Zelira is committed to evidence-based cannabinoid medicines and investing in clinical trials. We develop medicines designed to treat specific indications including chronic insomnia and behaviours associated with autism. Our insomnia trial was recently published in the prestigious Sleep journal. We're looking for partners for licensing and/or distribution into global markets including NZ. If this is of interest, please get in contact for an initial discussion.Greg BlakeVP – Global Head of Commercial and [email protected]
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.520M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 34234 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 5666 | 1 |
View Market Depth
| Last trade - 16.21pm 16/09/2025 (20 minute delay) ? |
| ZLD (ASX) Chart |
Day chart unavailable